- Home
- RAPT vs LUCD Comparison
RAPT vs LUCD Comparison
Compare RAPT & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- LUCD
- Stock Information
- Founded
- RAPT 2015
- LUCD 2018
- Country
- RAPT United States
- LUCD United States
- Employees
- RAPT N/A
- LUCD N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RAPT Health Care
- LUCD Health Care
- Exchange
- RAPT Nasdaq
- LUCD Nasdaq
- Market Cap
- RAPT 117.5M
- LUCD 140.7M
- IPO Year
- RAPT 2019
- LUCD 2021
- Fundamental
- Price
- RAPT $7.35
- LUCD $1.26
- Analyst Decision
- RAPT Buy
- LUCD Strong Buy
- Analyst Count
- RAPT 5
- LUCD 4
- Target Price
- RAPT $42.00
- LUCD $3.94
- AVG Volume (30 Days)
- RAPT 120.8K
- LUCD 1.3M
- Earning Date
- RAPT 08-07-2025
- LUCD 08-11-2025
- Dividend Yield
- RAPT N/A
- LUCD N/A
- EPS Growth
- RAPT N/A
- LUCD N/A
- EPS
- RAPT N/A
- LUCD N/A
- Revenue
- RAPT N/A
- LUCD $4,173,000.00
- Revenue This Year
- RAPT N/A
- LUCD $91.46
- Revenue Next Year
- RAPT N/A
- LUCD $213.42
- P/E Ratio
- RAPT N/A
- LUCD N/A
- Revenue Growth
- RAPT N/A
- LUCD 39.89
- 52 Week Low
- RAPT $5.67
- LUCD $0.68
- 52 Week High
- RAPT $30.60
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- RAPT 43.57
- LUCD 46.57
- Support Level
- RAPT $6.88
- LUCD $1.21
- Resistance Level
- RAPT $8.91
- LUCD $1.34
- Average True Range (ATR)
- RAPT 0.70
- LUCD 0.08
- MACD
- RAPT -0.16
- LUCD -0.01
- Stochastic Oscillator
- RAPT 11.36
- LUCD 50.00
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.